Literature DB >> 17497733

Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.

Valerie Autissier1, Stephen J P Damment, Richard A Henderson.   

Abstract

The high tablet burden and poor compliance associated with phosphate-binding drugs has led to a search for more potent agents. In vitro-binding studies were performed on the recently introduced binder, lanthanum carbonate (LC; Fosrenol), to compare its phosphate-binding affinity with sevelamer hydrochloride (SH; Renagel). Langmuir equilibrium binding affinities (K(1)) for LC and SH were established using different phosphorus (5-100 mM) and binder (134-670 mg per 50 mL) concentrations at pH 3-7, with or without salts of bile acids present (30 mM). At all pH levels, LC had a higher binding affinity for phosphate than SH. For LC, K(1) was 6.1 +/- 1.0 mM(-1) and was independent of pH. For SH, K(1) was pH dependent, being 1.5 +/- 0.8 mM(-1) at pH 5-7 and 0.025 +/- 0.002 mM(-1) at pH 3, that is, >200 times lower than for LC. In the presence of 30 mM bile salts, SH lost 50% of its phosphate, whereas no displacement of phosphate occurred for LC. These findings indicate that LC binds phosphate more effectively than SH across the pH range encountered in the gastrointestinal tract, and has a lower propensity for bound phosphate to be displaced by competing anions in the intestine. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17497733     DOI: 10.1002/jps.20956

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Pharmacology, efficacy and safety of oral phosphate binders.

Authors:  Alastair J Hutchison; Craig P Smith; Paul E C Brenchley
Journal:  Nat Rev Nephrol       Date:  2011-09-06       Impact factor: 28.314

2.  Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.

Authors:  Alastair J Hutchison; M Edwina Barnett; Rolfdieter Krause; Jonathan T C Kwan; Ghodrat A Siami
Journal:  Nephron Clin Pract       Date:  2008-07-31

3.  The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.

Authors:  David Pierce; Stuart Hossack; Lynne Poole; Antoine Robinson; Heather Van Heusen; Patrick Martin; Michael Smyth
Journal:  Nephrol Dial Transplant       Date:  2010-10-04       Impact factor: 5.992

Review 4.  Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Authors:  Stephen J P Damment; Michael Pennick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.

Authors:  Rajnish Mehrotra; Kevin J Martin; Steven Fishbane; Stuart M Sprague; Steven Zeig; Michael Anger
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 8.237

6.  A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.

Authors:  Felix Bronner; Boris M Slepchenko; Michael Pennick; Stephen J P Damment
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

8.  Pharmacology of the phosphate binder, lanthanum carbonate.

Authors:  Stephen J P Damment
Journal:  Ren Fail       Date:  2011       Impact factor: 2.606

9.  Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.

Authors:  Veerle P Persy; Geert J Behets; Marc E De Broe; Patrick C D'Haese
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-04-01

10.  Endotoxin binding by sevelamer: potential impact on nutritional status.

Authors:  Natsuki Kubotera; Alexander J Prokopienko; Adinoyi O Garba; Amy Barton Pai
Journal:  Int J Nephrol       Date:  2013-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.